Lisata Therapeutics & Valo Therapeutics: A Promising Preclinical Collaboration

Lisata Therapeutics, Inc. (Nasdaq: LSTA) and Valo Therapeutics Oy ("ValoTx") have announced a preclinical research collaboration to investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's innovative platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. This collaboration holds significant potential for enhancing melanoma treatment and offers an attractive investment opportunity.

Certepetide, an investigational drug designed to selectively activate the C-end rule active transport mechanism, has demonstrated promising results in modifying the tumor microenvironment and inhibiting the metastatic cascade. When combined with ValoTx's PeptiCRAd immunotherapy and a checkpoint inhibitor, this combination therapy has the potential to unlock new frontiers in cancer immunotherapy. By targeting the immunosuppressive nature of the tumor microenvironment and inhibiting the metastatic cascade, this approach could lead to improved patient outcomes by addressing resistance, recurrence, and metastasis challenges in melanoma treatment.

The collaboration between Lisata Therapeutics and Valo Therapeutics is a strategic move that leverages the complementary mechanisms of action of their respective therapies. Certepetide's ability to modify the tumor microenvironment, making it less immunosuppressive, complements the action of PeptiCRAd, which uses replicating adenoviruses to target cancer cells. The addition of a checkpoint inhibitor further enhances the therapeutic effect by blocking immune checkpoints and enabling T cells to recognize and attack cancer cells more effectively.


The combination of these therapies creates a multi-pronged attack on melanoma, offering a more effective and targeted treatment option. This approach has the potential to improve patient outcomes, reduce side effects, and address the challenges faced by current melanoma treatments.

Investing in Lisata Therapeutics and Valo Therapeutics presents an attractive opportunity for income-focused investors. Both companies are dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Their focus on stable profits and cash flows, as well as their commitment to addressing unmet medical needs, aligns with the author's core investment values.


In conclusion, the preclinical research collaboration between Lisata Therapeutics and Valo Therapeutics offers a promising investment opportunity for income-focused investors. The combination of their respective therapies holds significant potential for enhancing melanoma treatment and addressing the challenges faced by current treatments. By leveraging the complementary mechanisms of action of their therapies, this collaboration has the potential to lead to improved patient outcomes and create value for investors.